{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:08:26Z","timestamp":1761894506590},"reference-count":30,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"15","content-domain":{"domain":["www.ahajournals.org"],"crossmark-restriction":true},"short-container-title":["Circulation"],"published-print":{"date-parts":[[2007,4,17]]},"abstract":"<jats:p>\n            <jats:bold>\n              <jats:italic>Background\u2014<\/jats:italic>\n            <\/jats:bold>\n            Current guidelines for the treatment of hypertension do not provide specific recommendations for obese hypertensive patients. To identify an optimal treatment regimen for obese hypertensive patients, we studied the interactions between a drug-based weight loss approach by sibutramine and different antihypertensive drug regimens.\n          <\/jats:p>\n          <jats:p>\n            <jats:bold>\n              <jats:italic>Methods and Results\u2014<\/jats:italic>\n            <\/jats:bold>\n            This was a prospective, 16-week double-blind placebo-controlled randomized multicenter study in 171 obese hypertensive patients. After a 2-week run-in period, patients receiving 1 of the 3 antihypertensive combination therapies (felodipine 5 mg\/ramipril 5 mg [n=57], verapamil 180 mg\/trandolapril 2 mg [n=55], or metoprolol succinate 95 mg\/hydrochlorothiazide 12.5 mg [metoprolol\/hydrochlorothiazide; n=59]) were assigned randomly to sibutramine (15 mg) or placebo. Sibutramine treatment resulted in a significantly greater decrease in body weight, body mass index, and waist circumference and a significant increase in diastolic blood pressure during 24-hour blood pressure monitoring compared with placebo treatment. Sibutramine-induced weight loss and reduction of visceral obesity were markedly attenuated in the metoprolol\/hydrochlorothiazide group compared with the other groups. Consistently, improvement in glucose tolerance and hypertriglyceridemia by sibutramine was abrogated in the cohort treated with metoprolol\/hydrochlorothiazide compared with the other groups.\n          <\/jats:p>\n          <jats:p>\n            <jats:bold>\n              <jats:italic>Conclusions\u2014<\/jats:italic>\n            <\/jats:bold>\n            The present study demonstrates for the first time that an antihypertensive combination therapy regimen with angiotensin-converting enzyme inhibitors and calcium channel blockers is more advantageous than a \u03b2-blocker\/diuretic\u2013based regimen in supporting the weight-reducing actions and concomitant metabolic changes induced by sibutramine in obese hypertensive patients. These data may help to develop future comprehensive treatment strategies and guidelines for this high-risk patient population.\n          <\/jats:p>","DOI":"10.1161\/circulationaha.106.625400","type":"journal-article","created":{"date-parts":[[2007,4,3]],"date-time":"2007-04-03T00:58:39Z","timestamp":1175561919000},"page":"1991-1998","update-policy":"http:\/\/dx.doi.org\/10.1161\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":65,"title":["Optimal Treatment of Obesity-Related Hypertension"],"prefix":"10.1161","volume":"115","author":[{"given":"Ju\u0308rgen","family":"Scholze","sequence":"first","affiliation":[{"name":"From the Department of Medicine (J.S., E.G., D.H.), Outpatient Clinic, and Center for Cardiovascular Research (J.S., T.U., U.K.), Institute of Pharmacology, CCM, Charite\u0301-Universita\u0308tsmedizin Berlin, Berlin, Germany."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elmar","family":"Grimm","sequence":"additional","affiliation":[{"name":"From the Department of Medicine (J.S., E.G., D.H.), Outpatient Clinic, and Center for Cardiovascular Research (J.S., T.U., U.K.), Institute of Pharmacology, CCM, Charite\u0301-Universita\u0308tsmedizin Berlin, Berlin, Germany."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dana","family":"Herrmann","sequence":"additional","affiliation":[{"name":"From the Department of Medicine (J.S., E.G., D.H.), Outpatient Clinic, and Center for Cardiovascular Research (J.S., T.U., U.K.), Institute of Pharmacology, CCM, Charite\u0301-Universita\u0308tsmedizin Berlin, Berlin, Germany."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Unger","sequence":"additional","affiliation":[{"name":"From the Department of Medicine (J.S., E.G., D.H.), Outpatient Clinic, and Center for Cardiovascular Research (J.S., T.U., U.K.), Institute of Pharmacology, CCM, Charite\u0301-Universita\u0308tsmedizin Berlin, Berlin, Germany."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ulrich","family":"Kintscher","sequence":"additional","affiliation":[{"name":"From the Department of Medicine (J.S., E.G., D.H.), Outpatient Clinic, and Center for Cardiovascular Research (J.S., T.U., U.K.), Institute of Pharmacology, CCM, Charite\u0301-Universita\u0308tsmedizin Berlin, Berlin, Germany."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"e_1_3_2_1_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.293.15.1868"},{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.cir.0000140086.88453.9a"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004872-200306000-00001"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-139-11-200312020-00013"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.279.11.839"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)67483-1"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004872-200104000-00001"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1002\/j.1550-8528.1999.tb00701.x"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)03491-7"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.286.11.1331"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.cir.0000036370.31856.73"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ijo.0802887"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1038\/oby.2001.13"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.2337\/diab.41.7.826"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(87)91605-9"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)67402-8"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ijo.0801204"},{"key":"e_1_3_2_18_2","first-page":"S38","volume":"22","year":"1998","unstructured":"Van Gaal LF, Wauters MA, Peiffer FW, De Leeuw IH. Sibutramine and fat distribution: is there a role for pharmacotherapy in abdominal\/visceral fat reduction? Int J Obes Relat Metab Disord. 1998; 22: S38\u2013S40.","journal-title":"Int J Obes Relat Metab Disord"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1161\/hyp.37.2.250"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004872-198710000-00009"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1161\/hyp.36.1.26"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1467-789x.2001.00010.x"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.hjh.0000177537.91527.09"},{"key":"e_1_3_2_24_2","first-page":"257","volume":"8","year":"1994","unstructured":"Samuelsson O, Hedner T, Berglund G, Persson B, Andersson OK, Wilhelmsen L. Diabetes mellitus in treated hypertension: incidence, predictive factors and the impact of non-selective beta-blockers and thiazide diuretics during 15 years treatment of middle-aged hypertensive men in the Primary Prevention Trial Goteborg, Sweden. J Hum Hypertens. 1994; 8: 257\u2013263.","journal-title":"J Hum Hypertens"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjhyper.2005.09.009"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.292.18.2227"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198909283211305"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.jhh.1001297"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197801052980101"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(98)04311-6"}],"container-title":["Circulation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ahajournals.org\/doi\/full\/10.1161\/CIRCULATIONAHA.106.625400","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T04:58:21Z","timestamp":1715576301000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ahajournals.org\/doi\/10.1161\/CIRCULATIONAHA.106.625400"}},"subtitle":["The Hypertension-Obesity-Sibutramine (HOS) Study"],"short-title":[],"issued":{"date-parts":[[2007,4,17]]},"references-count":30,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2007,4,17]]}},"alternative-id":["10.1161\/CIRCULATIONAHA.106.625400"],"URL":"https:\/\/doi.org\/10.1161\/circulationaha.106.625400","relation":{},"ISSN":["0009-7322","1524-4539"],"issn-type":[{"value":"0009-7322","type":"print"},{"value":"1524-4539","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,4,17]]},"assertion":[{"value":"2007-04-02","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}